Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 1)
Liraglutide Injection
Product Images NDC 70748-346
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 70748-346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 10)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 11)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 12)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 13)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 14)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 15)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 16)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 17)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 18)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 19)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 2)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 3)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 4)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 5)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 6)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 7)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 8)
Image (0302ba5a E4e3 4fc9 B205 1dfa00d2246a 151 9)
Image (673a6213 Cf00 4aba Bcf7 47954d59231e 01)
Image (673a6213 Cf00 4aba Bcf7 47954d59231e 02)
Image (673a6213 Cf00 4aba Bcf7 47954d59231e 03)
This text provides information about a comparative study involving Liraglutide Injection, Glimepride, and Placebo in terms of Mean HbA1c levels over time (weeks). It highlights p-values indicating significance when comparing Liraglutide Injections at different dosages to Glimepride. The study suggests that both dosages of Liraglutide Injections resulted in significant changes compared to Glimepride.*
Image (673a6213 Cf00 4aba Bcf7 47954d59231e 04)
Image (673a6213 Cf00 4aba Bcf7 47954d59231e 05)
This text is a description of the components of a Liraglutide Pen, including the cartridge scale, pen cap, rubber stopper, needles, protective shields, dose selector, and a contact number and website for assistance in case of any issues with using the Liraglutide Injection Pen.*
Img 1 (673a6213 Cf00 4aba Bcf7 47954d59231e 06)
The text provides information on the expiry date format for human-readable data and 2D format along with the requirements to overprint details such as GTIN, S/N, EXP, and LOT at the plant. It also mentions the size specifications for the area where the data matrix should be printed. Additionally, details about the ingredients of the product, directions for use, storage instructions, and manufacturer information are included. The text seems to pertain to Liraglutide Injection, specifying its components, dosage, storage conditions, and manufacturer details.*
Img 2 (673a6213 Cf00 4aba Bcf7 47954d59231e 07)
This text provides information on the expiry date format, packaging details, usage instructions, and ingredients for Liraglutide Injection. It mentions the requirement for overprinting important information like GTIN, S/N, EXP, and LOT on the packaging at the plant. The text also includes dosage information, storage instructions, and a directive to contact a pharmacist for further assistance. The product is for subcutaneous use only and needs to be refrigerated but not frozen. The dosage strength is 18 mg/3 mL.*
Image (673a6213 Cf00 4aba Bcf7 47954d59231e 163 2)
Image (Dfd8faeb 066c 4938 9833 Fabc2dd3c94b 142 1)
Image (Dfd8faeb 066c 4938 9833 Fabc2dd3c94b 156 1)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
